News | December 03, 2008

St. Jude Launches QuickOpt Timing Cycle Optimization for Defibrillators in Japan

December 4, 2008 - St. Jude Medical Inc. this week said it received expanded approval from the Japanese Ministry of Health, Labour and Welfare for the QuickOpt Timing Cycle Optimization feature in the Epic HF and Atlas HF cardiac resynchronization therapy defibrillators (CRT-Ds).

CRT-Ds are implantable cardioverter defibrillators (ICDs) that help prevent sudden cardiac arrest and treat heart failure by synchronizing heart rhythms. The QuickOpt capability allows physicians to easily test and optimize a patient’s CRT-D to ensure that its pacing rhythm is customized to the individual patient’s needs. This is important because heart disease is different in each patient, so optimizing the devices helps to ensure that each patient receives the full benefit of device therapy.

Optimized timing can increase the efficiency of the heart’s ability to pump blood to the body. The company said at a fraction of the time and cost of conventional echocardiogram-based optimizations, the QuickOpt feature can help physicians optimize more patients in less time through a simple procedure. In 90 seconds during a regular follow-up visit, the QuickOpt feature can recommend the optimal A-V (atrial-ventricular) and V-V (ventricular-ventricular) timing values to use in programming the devices.

“QuickOpt optimization gives me the ability to precisely program the device to meet each patient’s specific needs for treating their heart failure,” said Hiroshi Nakajima, M.D., of Itabashi Chuo Medical Center. “It allows me to check my patients’ devices and adjust the timing whenever needed so that the therapy can be continuously optimized for each patient.”

Traditional echocardiography (echo), while considered the gold standard for optimizing devices, can be expensive and time-consuming. The company said QuickOpt feature produces results clinically proven to be comparable with those of echo, in 90 seconds instead of the 30 to 120 minutes required for a typical echo.

For more information: www.sjm.com


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

Sept. 2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter ...

Home September 05, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
Subscribe Now